Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol Myers (BMY) announces AXIOMATIC-SSP study results of milvexian, an investigational oral factor XIa inhibitor, for preventing new symptomatic ischemic stroke or new covert brain infarction.

Bristol Myers (BMY) Announces Milvexian Phase II Study Results

While the therapy, milvexian, showed a 30% risk reduction in recurrent ischemic strokes among people who showed symptoms, it didn't have an effect on covert infarcts, eroding investor confidence.

Bristol Myers Stock Falls After Stroke Medicine Misses the Mark

Bayer AG

Bristol Myers and Johnson & Johnson's blood thinner fell short of expectations in stroke patients, leading BMY stock to crumble on Monday. The post Bristol Myers Squibb, Bayer Stocks Hit The Deck On Blood Thinner Flops appeared first on Investor's Business Daily.

Bristol Myers Squibb, Bayer Stocks Hit The Deck On Blood Thinner Flops

Johnson & Johnson

Investors should keep an eye on developments at the European Society of Cardiology meeting, which is underway in Barcelona. News about a new type of heart drug being tested by Bristol-Myers Squibb Co. ( BMY , Financial), Johnson & Johnson ( JNJ , Financial) and Bayer AG ( XTER:BAYN , Financial) could potentially move the shares of the three pharmaceutical giants.

Bristol-Myers, J&J and Bayer Presenting Key Study Results at Heart Meeting

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #AXIOMATIC--Late-Breaking Results From Phase 2 AXIOMATIC-SSP Study of Milvexian

Late-Breaking Results From Phase 2 AXIOMATIC-SSP Study of Milvexian, an Investigational Oral Factor XIa Inhibitor, Show Favorable Antithrombotic Profile in Combination With Dual Antiplatelet Therapy

Bristol Myers (BMY) has put up an impressive performance so far in 2022, and the momentum should continue on label expansion of existing drugs.

Bristol Myers (BMY) Up 14.6% YTD: Will the Performance Continue?

BOSTON--(BUSINESS WIRE)--PathAI, a global leader in AI-powered pathology, today announced a multi-year expanded collaboration agreement with Bristol Myers Squibb. The initial work within this extended agreement will focus on key translational research in oncology, fibrosis, and immunology, with an overall goal to continue transitioning this work into clinical trials. “We look forward to collaborating with PathAI to expand the potential application of AI in the drug development process to includ

PathAI Announces Extension of Multi-Year Collaboration Agreement with Bristol Myers Squibb

AbbVie

Royalty Pharma

The Oracle of Omaha doesn't like pharma stocks for some reason.

Do Warren Buffett's Recent Moves Spell Doom for This Group of Stocks?

High-yield stocks tend to outperform during downturns in the broader market.

3 Reasons to Buy This High-Yield Dividend Stock

Apple

Booking Hlds

GEO Group

"The Big Short" investor has raised a lot of eyebrows with his latest trade.

Michael Burry Sold All of His Holdings and Bought This Controversial Stock

Cisco Systems

McDonald's

3 High-Yielding Dividend Stocks That Are Ideal for Retirees

NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology Portfolio

Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology Portfolio

NEW YORK & SAN DIEGO--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and Clearance from SEE RELEASE FOR FULL TITLE

Bristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and Clearance from Federal Cartel Office of Germany Related to Pending Acquisition of Turning Point Therapeutics

Exelixis

These two drug makers have outshined the market this year.

2 No-Brainer Bio-Tech Stocks to Buy Right Now

Bristol Myers (BMY) and partner, 2seventy bio, report top-line data from a late-stage study evaluating Abecma for multiple myeloma patients after two or more lines of prior therapy.

Bristol Myers (BMY) Posts Data From Multiple Myeloma Study

AmerisourceBergen

Quest Diagnostics

HCA Healthcare

Labcorp Holdings Inc

McKesson

Merck

Pfizer

Viatris

The S&P 500 Index has rallied 10% since June 22 from a deep decline, but there are different schools of thought about whether investors are out of the woods yet.

10 defensive stocks that can also provide you with growth and dividends over the long term

PRINCETON, N.J., & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) SEE RELEASE FOR FULL TITLE

Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) Significantly Improves Progression-Free Survival Versus Standard Regimens in Relapsed and Refractory Multiple Myeloma

Bristol Myers Squibb is attractive with a 10% earnings yield, 3% dividend yield, and tenacious performance over the last several quarters. Growth is lacking as BMY is losing market share to generic alternatives, especially for important earner Revlimid.

Earning 10% Income On Bristol Myers Squibb With Options

Bristol Myers Squibb stock (NYSE: BMY) reported its Q2 results last week, with revenue and earnings coming in above ours and the street estimates.

What's Next For Bristol Myers Squibb Stock?

AstraZeneca

When the market is falling, this trio keeps rising.

3 Unstoppable Stocks That Don't Care About the Bear Market

Income investors have a lot to like about these stocks.

3 Unstoppable Dividend Stocks to Buy in August

These two drugmakers are outpacing the market this year.

2 Stocks That Could Lead the Market Recovery

NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb to Host Virtual Investor Event to Discuss ESC 2022 Highlights

Bristol Myers Squibb to Host Virtual Investor Event to Discuss ESC 2022 Highlights

Will Bristol-Myers Squibbs' pipeline and newly approved drugs overcome its expiring patents?

Famed "Big Short" Investor Loves This Multibillion-Dollar Company -- Should You?

Seagen

Biogen

BioMarin Pharmaceutical

Medpace Holdings

Thermo Fisher Scientific

Zimmer Biomet Hlds

You're tempted to increase exposure to stocks because of the market's strength. But you're still gun shy because of the painful selloff.

News for Bristol-Myers Stock (BMY)